Last reviewed · How we verify
tolterodine , mirabegron
Tolterodine and mirabegron work together to reduce overactive bladder symptoms through complementary pathways: tolterodine blocks muscarinic receptors to decrease bladder contractions, while mirabegron activates beta-3 adrenergic receptors to relax the detrusor muscle.
Tolterodine and mirabegron work together to reduce overactive bladder symptoms through complementary pathways: tolterodine blocks muscarinic receptors to decrease bladder contractions, while mirabegron activates beta-3 adrenergic receptors to relax the detrusor muscle. Used for Overactive bladder with symptoms of urgency, frequency, and urgency incontinence.
At a glance
| Generic name | tolterodine , mirabegron |
|---|---|
| Sponsor | Far Eastern Memorial Hospital |
| Drug class | Antimuscarinic and beta-3 adrenergic agonist combination |
| Target | Muscarinic M3 receptor and beta-3 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | FDA-approved |
Mechanism of action
Tolterodine is an antimuscarinic agent that inhibits acetylcholine signaling in the bladder, reducing involuntary contractions. Mirabegron is a beta-3 adrenergic agonist that increases norepinephrine-mediated relaxation of the bladder smooth muscle. Together, they provide dual mechanism coverage for overactive bladder, potentially offering improved efficacy over monotherapy.
Approved indications
- Overactive bladder with symptoms of urgency, frequency, and urgency incontinence
Common side effects
- Dry mouth
- Constipation
- Headache
- Dizziness
- Hypertension
- Urinary retention
Key clinical trials
- TReating Incontinence for Underlying Mental and Physical Health (PHASE4)
- Deprescribing dRrugs for Overactive Bladder in General Practice (DROP) (NA)
- The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial (PHASE3)
- Efficacy of Low-Intensity Shockwave Therapy in Treating Radiation Cystitis (EARLY_PHASE1)
- A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain (PHASE3)
- Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (PHASE3)
- Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (PHASE3)
- Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- tolterodine , mirabegron CI brief — competitive landscape report
- tolterodine , mirabegron updates RSS · CI watch RSS
- Far Eastern Memorial Hospital portfolio CI